Literature DB >> 34921299

Renal denervation: basic and clinical evidence.

Kenichi Katsurada1,2, Keisuke Shinohara3,4, Jiro Aoki5, Shinsuke Nanto6, Kazuomi Kario7.   

Abstract

Renal nerves have critical roles in regulating blood pressure and fluid volume, and their dysfunction is closely related with cardiovascular diseases. Renal nerves are composed of sympathetic efferent and sensory afferent nerves. Activation of the efferent renal sympathetic nerves induces renin secretion, sodium absorption, and increased renal vascular resistance, which lead to increased blood pressure and fluid retention. Afferent renal sensory nerves, which are densely innervated in the renal pelvic wall, project to the hypothalamic paraventricular nucleus in the brain to modulate sympathetic outflow to the periphery, including the heart, kidneys, and arterioles. The effects of renal denervation on the cardiovascular system are mediated by both efferent denervation and afferent denervation. The first half of this review focuses on basic research using animal models of hypertension and heart failure, and addresses the therapeutic effects of renal denervation for hypertension and heart failure, including underlying mechanisms. The second half of this review focuses on clinical research related to catheter-based renal denervation in patients with hypertension. Randomized sham-controlled trials using second-generation devices, endovascular radiofrequency-based devices and ultrasound-based devices are reviewed and their results are assessed. This review summarizes the basic and clinical evidence of renal denervation to date, and discusses future prospects and potential developments in renal denervation therapy for cardiovascular diseases.
© 2021. The Author(s), under exclusive licence to The Japanese Society of Hypertension.

Entities:  

Keywords:  Heart failure; Hypertension; Radiofrequency renal denervation; Sympathetic nervous system; Ultrasound renal denervation

Mesh:

Year:  2021        PMID: 34921299     DOI: 10.1038/s41440-021-00827-7

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  46 in total

1.  Fos induction in central structures after afferent renal nerve stimulation.

Authors:  L P Solano-Flores; M P Rosas-Arellano; J Ciriello
Journal:  Brain Res       Date:  1997-04-04       Impact factor: 3.252

Review 2.  Renal Nerves and Long-Term Control of Arterial Pressure.

Authors:  John W Osborn; Jason D Foss
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

3.  Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial.

Authors:  Michel Azizi; Roland E Schmieder; Felix Mahfoud; Michael A Weber; Joost Daemen; Justin Davies; Jan Basile; Ajay J Kirtane; Yale Wang; Melvin D Lobo; Manish Saxena; Lida Feyz; Florian Rader; Philipp Lurz; Jeremy Sayer; Marc Sapoval; Terry Levy; Kintur Sanghvi; Josephine Abraham; Andrew S P Sharp; Naomi D L Fisher; Michael J Bloch; Helen Reeve-Stoffer; Leslie Coleman; Christopher Mullin; Laura Mauri
Journal:  Lancet       Date:  2018-05-23       Impact factor: 79.321

4.  Renal sensory nerves increase sympathetic nerve activity and blood pressure in 2-kidney 1-clip hypertensive mice.

Authors:  Jason Ong; Brian J Kinsman; Alan F Sved; Brittney M Rush; Roderick J Tan; Marcelo D Carattino; Sean D Stocker
Journal:  J Neurophysiol       Date:  2019-05-15       Impact factor: 2.714

5.  A novel method of selective ablation of afferent renal nerves by periaxonal application of capsaicin.

Authors:  Jason D Foss; Richard D Wainford; William C Engeland; Gregory D Fink; John W Osborn
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-11-19       Impact factor: 3.619

6.  Resting Afferent Renal Nerve Discharge and Renal Inflammation: Elucidating the Role of Afferent and Efferent Renal Nerves in Deoxycorticosterone Acetate Salt Hypertension.

Authors:  Christopher T Banek; Mark M Knuepfer; Jason D Foss; Jessica K Fiege; Ninitha Asirvatham-Jeyaraj; Dusty Van Helden; Yoji Shimizu; John W Osborn
Journal:  Hypertension       Date:  2016-10-03       Impact factor: 10.190

7.  Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial.

Authors:  Michael Böhm; Kazuomi Kario; David E Kandzari; Felix Mahfoud; Michael A Weber; Roland E Schmieder; Konstantinos Tsioufis; Stuart Pocock; Dimitris Konstantinidis; James W Choi; Cara East; David P Lee; Adrian Ma; Sebastian Ewen; Debbie L Cohen; Robert Wilensky; Chandan M Devireddy; Janice Lea; Axel Schmid; Joachim Weil; Tolga Agdirlioglu; Denise Reedus; Brian K Jefferson; David Reyes; Richard D'Souza; Andrew S P Sharp; Faisal Sharif; Martin Fahy; Vanessa DeBruin; Sidney A Cohen; Sandeep Brar; Raymond R Townsend
Journal:  Lancet       Date:  2020-03-29       Impact factor: 79.321

8.  Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial.

Authors:  David E Kandzari; Michael Böhm; Felix Mahfoud; Raymond R Townsend; Michael A Weber; Stuart Pocock; Konstantinos Tsioufis; Dimitrios Tousoulis; James W Choi; Cara East; Sandeep Brar; Sidney A Cohen; Martin Fahy; Garrett Pilcher; Kazuomi Kario
Journal:  Lancet       Date:  2018-05-23       Impact factor: 79.321

9.  Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial.

Authors:  Michel Azizi; Kintur Sanghvi; Manish Saxena; Philippe Gosse; John P Reilly; Terry Levy; Lars C Rump; Alexandre Persu; Jan Basile; Michael J Bloch; Joost Daemen; Melvin D Lobo; Felix Mahfoud; Roland E Schmieder; Andrew S P Sharp; Michael A Weber; Marc Sapoval; Pete Fong; Atul Pathak; Pierre Lantelme; David Hsi; Sripal Bangalore; Adam Witkowski; Joachim Weil; Benjamin Kably; Neil C Barman; Helen Reeve-Stoffer; Leslie Coleman; Candace K McClure; Ajay J Kirtane
Journal:  Lancet       Date:  2021-05-16       Impact factor: 79.321

10.  Renal Sensory Activity Regulates the γ-Aminobutyric Acidergic Inputs to the Paraventricular Nucleus of the Hypothalamus in Goldblatt Hypertension.

Authors:  Maycon I O Milanez; Amanda C Veiga; Beatriz S Martins; Roberto B Pontes; Cassia T Bergamaschi; Ruy R Campos; Erika E Nishi
Journal:  Front Physiol       Date:  2020-12-15       Impact factor: 4.566

View more
  5 in total

Review 1.  Circadian clocks of the kidney: function, mechanism, and regulation.

Authors:  Hannah M Costello; Jermaine G Johnston; Alexandria Juffre; G Ryan Crislip; Michelle L Gumz
Journal:  Physiol Rev       Date:  2022-05-16       Impact factor: 46.500

Review 2.  Cardiorenal Syndrome: The Role of Neural Connections Between the Heart and the Kidneys.

Authors:  Kaushik P Patel; Kenichi Katsurada; Hong Zheng
Journal:  Circ Res       Date:  2022-05-12       Impact factor: 23.213

3.  Latest hypertension research to inform clinical practice in Asia.

Authors:  Kazuomi Kario; Masaki Mogi; Satoshi Hoshide
Journal:  Hypertens Res       Date:  2022-04-05       Impact factor: 5.528

4.  2022 Malaysian Working Group Consensus Statement on Renal Denervation for management of arterial hypertension.

Authors:  Yook Chin Chia; Wan Azman Wan Ahmad; Alan Yean Yip Fong; Azhari Rosman; Abdul Rashid Abdul Rahman; Gim Hooi Choo; Soo Kun Lim; Mohammad Zawawi Abu Bakar; Tiong Kiam Ong
Journal:  Hypertens Res       Date:  2022-06-01       Impact factor: 5.528

Review 5.  Update on Hypertension Research in 2021.

Authors:  Masaki Mogi; Tatsuya Maruhashi; Yukihito Higashi; Takahiro Masuda; Daisuke Nagata; Michiaki Nagai; Kanako Bokuda; Atsuhiro Ichihara; Yoichi Nozato; Ayumi Toba; Keisuke Narita; Satoshi Hoshide; Atsushi Tanaka; Koichi Node; Yuichi Yoshida; Hirotaka Shibata; Kenichi Katsurada; Masanari Kuwabara; Takahide Kodama; Keisuke Shinohara; Kazuomi Kario
Journal:  Hypertens Res       Date:  2022-07-05       Impact factor: 5.528

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.